Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 225

Sort by

Sort Order Select

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Bone Marrow Plasma Cell Burden in Gaucher Disease Correlates with Local Macrophage Infiltration and May be Altered By Disease Treatment

Monika Klimkowska, MD PhD, Maciej J. Machaczka, MD PhD

Blood (2019) 134 (Supplement_1): 3593.

https://doi.org/10.1182/blood-2019-131343

Published: 2019

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

Blood (2019) 134 (Supplement_1): 693.

https://doi.org/10.1182/blood-2019-125120

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Silvia Mangiacavalli, Zacchino Michela, MD, Virginia Valeria Ferretti, Claudio Salvatore Cartia, MD, Giovanni Savietto, MD, Pietro Benvenuti, MD, Marzia Varettoni, Sara Rattotti, Brociner Marco, Gabriele Merati, MD, Luca Arcaini

Blood (2019) 134 (Supplement_1): 5495.

https://doi.org/10.1182/blood-2019-126422

Published: 2019

Journal Articles

Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma

Ben A Derman, MDBA, Meytal Chernoff, BS, Andrzej Jakubowiak, MD PhD, Brian C.-H. Chiu, PhD

Blood (2019) 134 (Supplement_1): 5494.

https://doi.org/10.1182/blood-2019-126304

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma

Smith Giri, MBBS, Ellice Y. Wong, MD, Michal Rose, MD, Roxanne Wadia, MD, Lesley S. Park, PhD MPH, Amy C. Justice, MD PhD, Natalia Neparidze, MD

Blood (2018) 132 (Supplement 1): 3162.

https://doi.org/10.1182/blood-2018-99-115633

Published: 2018

Journal Articles

Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review

Insija Ilyas Selene, MBBS, Jemin Aby Jose, MD, Muhammad Jahanzeb Khalil, MD, Muhammad Junaid Tariq, MD, Seren Durer, MD, Ceren Durer, MD, Madeeha Shafqat, Shehroz Aslam, MD, Zunairah Shah, MBBS, Anum Qureshi, Faiza Jamil, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Muhammad Masab, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 3309.

https://doi.org/10.1182/blood-2018-99-116959

Published: 2018

Journal Articles

Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients

Anna Wing, Wenzhao Meng, PhD, Gerald Wertheim, MD, PhD, Dale Frank, MD, Michele Paessler, D.O., Megan S. Lim, MD, PhD, Eline T. Luning Prak, MD, PhD, David C Fajgenbaum, MD MBA, MSc, Vinodh Pillai, MD, PhD

Blood (2018) 132 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2018-99-116487

Published: 2018

Journal Articles

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Evangelos Terpos, MD PhD, Maria Roussou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Despina Fotiou, MD, Dimitrios C. Ziogas, MD, Aristea-Maria Papanota, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Efstathios Kastritis, MD, Meletios A Dimopoulos, MD

Blood (2018) 132 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2018-99-113108

Published: 2018

Journal Articles

Characterization of Patients with Multiple Myeloma in Long- Term Remission

Raphael K. Lutz, MD, Katharina Kriegsmann, MD MBA, Mohamed H.S. Awwad, Carsten Müller-Tidow, MD, Gerlinde Egerer, Nicola Lehners, Marc S Raab, MD PhD, Brian GM Durie, MD, Michael Hundemer, Hartmut Goldschmidt, MD

Blood (2018) 132 (Supplement 1): 4508.

https://doi.org/10.1182/blood-2018-99-116039

Published: 2018

Journal Articles

V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma

Even H Rustad, MD, Malin Hultcrantz, MD PhD, Venkata D Yellapantula, Theresia Akhlaghi, BS, Caleb Ho, MD, Maria E Arcila, MD, Mikhail Roshal, MD PhD, Akshar Patel, BA, Sean M Devlin, PhD, Austin Jacobsen, Ying Huang, PhD, Jeffrey E Miller, PhD, Elli Papaemmanuil, PhD, Ola Landgren, MD PhD

Blood (2018) 132 (Supplement 1): 4444.

https://doi.org/10.1182/blood-2018-99-113889

Published: 2018

Journal Articles

Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome

Dustin Shilling, PhD, Dale M Kobrin, BA, David C Fajgenbaum, MD MBA, MSc

Blood (2018) 132 (Supplement 1): 1121.

https://doi.org/10.1182/blood-2018-99-118434

Published: 2018

Journal Articles

Update on Severe Isotype-Matched Immunosuppression By Hevylite ® Confirms Its Predictive Value in MGUS Patients: A Real-Life Study

Juana Jimenez, MD, Nuno Barbosa, Tiago Moreira Pais, Maria Luisa Campos, Mª Antonia Peñálver, Carmen Hernando de Larramendi

Blood (2018) 132 (Supplement 1): 5583.

https://doi.org/10.1182/blood-2018-99-118212

Published: 2018

Journal Articles

Association between Immunoglobulin Isotypes and Cytogenetic Risk Groups in Multiple Myeloma

Ramya Muddasani, DO, Albert Ho, MD PhD, Meredith Akerman, PhD, Shahidul Islam, MPH, PStat, Mitchel Polak, Jamie Andres Suarez-Londono, MD, Marc Braunstein, MD PhD

Blood (2018) 132 (Supplement 1): 5585.

https://doi.org/10.1182/blood-2018-99-118831

Published: 2018

Journal Articles

Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience

Matthew J. Pianko, MD, Timothy Tiutan, MD, Jessica Flynn, BS, Sean M Devlin, PhD, Insara Jaffer-Sathick, MBBS, Adriana C. Rossi, MD MSc, Steven P. Salvatore, MD, Heather J. Landau, MD, Nikoletta Lendvai, MD PhD, Eric L. Smith, MD PhD, Neha Korde, MD, Sham Mailankody, MBBS, Alexander M. Lesokhin, MD, Malin Hultcrantz, MD PhD, David J. Chung, MD PhD, Sergio Giralt, MD, Ola Landgren, MD PhD, Hani Hassoun, MD

Blood (2018) 132 (Supplement 1): 5591.

https://doi.org/10.1182/blood-2018-99-112110

Published: 2018

Journal Articles

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

Simone A Minnie, David Smith, Kate H Gartlan, PhD, Thomas S Watkins, Kate A Markey, PhD MBBS, Camille Guillerey, PhD, Rachel D Kuns, BSc, Kelly R Locke, Antiopi Varelias, PhD, Ping Zhang, Nicholas Huntington, PhD, Marta Chesi, PhD, John J Miles, PhD, Mark J Smyth, PhD, Slavica Vuckovic, PhD, Geoffrey R Hill, MD PhD

Blood (2018) 132 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2018-99-118058

Published: 2018

Journal Articles

Bone Marrow Tracer Uptake Pattern of PET/CT in Multiple Myeloma: Image Interpretation Criteria and Prognostic Value

Jing Li, MD, Hui Tan, PhD, Tianhong Xu, Hongcheng Shi, PhD, Peng Liu, MD

Blood (2018) 132 (Supplement 1): 1900.

https://doi.org/10.1182/blood-2018-99-114370

Published: 2018

NARROW

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Bone Marrow Plasma Cell Burden in Gaucher Disease Correlates with Local Macrophage Infiltration and May be Altered By Disease Treatment

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE

Racial Differences in High-Risk Cytogenetic Mutations and Outcomes in Multiple Myeloma

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma

Presentation Pattern, Diagnostic Markers, Management and Outcome of IgD Multiple Myeloma: A Systematic Review

Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients

Functional Cure, Defined As PFS of More Than 7 Years, Is Achieved in 9% of Myeloma Patients in the Era of Conventional Chemotherapy and of First-Generation Novel Anti-Myeloma Agents; A Single-Center Experience over 20-Year Period

Characterization of Patients with Multiple Myeloma in Long- Term Remission

V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma

Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome

Update on Severe Isotype-Matched Immunosuppression By Hevylite ® Confirms Its Predictive Value in MGUS Patients: A Real-Life Study

Association between Immunoglobulin Isotypes and Cytogenetic Risk Groups in Multiple Myeloma

Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

Bone Marrow Tracer Uptake Pattern of PET/CT in Multiple Myeloma: Image Interpretation Criteria and Prognostic Value

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only